CTOs on the Move

Daiichi Sankyo

www.dsi.com

 
Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. With over 100 years of scientific expertise and a presence in more ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.dsi.com
  • 211 Mt. Airy Road
    Basking Ridge, NJ USA 07920
  • Phone: 908.992.6400

Executives

Name Title Contact Details
Paulette Gangemi
Senior Director, Employee Relations and Employment Practices (HR) Profile

Similar Companies

Novara Tesija Michela and Priehs

Novara Tesija Michela and Priehs is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RNL BioStar

RNL BioStar Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OmniAb

OmniAb is a leading edge antibody discovery company that provides access to diverse antibody repertoires and high throughput screening technologies. They specialize in therapeutic antibody discovery using chickens as immunization hosts, which allows fo...

St. Patricks Hospital

St. Patricks Hospital is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Moderna Therapeutics

Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck.